SELLAS Life Sciences Group Inc. (SLS) Making Progress on Key Acute Myeloid Leukemia Treatment

2 weeks ago 5

Abdul Rahman

Tue, April 14, 2026 astatine 4:55 AM CDT 2 min read

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the champion healthcare penny stocks to bargain according to hedge funds. On March 19, Chief Executive Officer Angelos Stergiou reiterated that 2026 is poised to beryllium a pivotal twelvemonth for Sellas Life Sciences Group Inc. (NASDAQ:SLS). The remarks align with the important advancement the institution is making successful its cardinal GPS and SLS009 objective programs.

SELLAS Life Sciences Group Inc. (SLS) Making Progress connected Key Acute Myeloid Leukemia Treatment

The institution is moving towards the last investigation of the Phase 3 REGAL proceedings of GPS successful AML patients pursuing second-line salvage therapy. Positive REGAL proceedings results could presumption it arsenic the archetypal and best-in-class immunotherapeutic enactment successful this AML population.

Sellas Life Sciences is besides making important advancement successful processing the SLS009 objective programme for AML. Following affirmative Phase 2 results successful high-risk molecular subtypes, the institution has started dosing the archetypal diligent successful the enlargement cohort. Preclinical information successful T-PLL demonstrated a statistically important endurance payment for SLS009 arsenic monotherapy and successful operation with venetoclax.

In the archetypal quarter, the institution received an further $42.6 cardinal successful proceeds from warrant exercises, further bolstering its reported $71.8 cardinal successful currency and currency equivalents arsenic of the extremity of past year. Consequently, the institution remains successful a beardown fiscal presumption to beforehand the objective trials.

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is simply a late-stage objective biopharmaceutical institution processing caller immunotherapies and targeted therapies for a wide scope of cancers. Its halfway absorption is treating hematological malignancies and coagulated tumors, with pb candidates targeting WT1 antigen overexpression and CDK9 inhibition to amended endurance and trim relapse.

While we admit the imaginable of SLS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 7 Penny Stocks That Aren’t Scams: Best Cheap Stocks to Buy and 8 Best Small-Cap Value Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article